These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 27934678)

  • 41. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
    Piaserico S; Messina F; Russo FP
    Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
    Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
    Rodríguez-Tajes S; Miralpeix A; Costa J; López-Suñé E; Laguno M; Pocurull A; Lens S; Mariño Z; Forns X
    J Viral Hepat; 2021 Jan; 28(1):89-94. PubMed ID: 32969557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
    J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
    Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
    Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis B virus reactivation during belatacept treatment after kidney transplantation.
    Cambier ML; Canestri A; Lependeven C; Peltier J; Mesnard L; Dahan K
    Transpl Infect Dis; 2019 Dec; 21(6):e13170. PubMed ID: 31505095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
    Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
    World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
    Sagnelli C; Pisaturo M; Calò F; Martini S; Sagnelli E; Coppola N
    World J Gastroenterol; 2019 Jul; 25(26):3299-3312. PubMed ID: 31341357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
    Mücke VT; Mücke MM; Peiffer KH; Weiler N; Welzel TM; Sarrazin C; Zeuzem S; Berger A; Vermehren J
    Aliment Pharmacol Ther; 2017 Aug; 46(4):432-439. PubMed ID: 28627791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
    Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
    J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection.
    Kamitsukasa H; Iri M; Tanaka A; Nagashima S; Takahashi M; Nishizawa T; Okamoto H
    J Med Virol; 2015 Apr; 87(4):589-600. PubMed ID: 25612181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies].
    Endo T; Sawada K; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T
    Rinsho Ketsueki; 2000 Apr; 41(4):322-8. PubMed ID: 10846463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.
    Kim YJ; Bae SC; Sung YK; Kim TH; Jun JB; Yoo DH; Kim TY; Sohn JH; Lee HS
    J Rheumatol; 2010 Feb; 37(2):346-50. PubMed ID: 20008922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of different hepatitis B infection status on the prognosis of active lupus nephritis treated with immunosuppression: a retrospective analysis of 177 patients.
    Fang J; Li W; Tan M; Peng X; Tan Z; Wang W
    Int J Rheum Dis; 2018 May; 21(5):1060-1067. PubMed ID: 29878614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis.
    Morisco F; Guarino M; La Bella S; Di Costanzo L; Caporaso N; Ayala F; Balato N
    BMC Gastroenterol; 2014 Dec; 14():214. PubMed ID: 25523080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy.
    Liu HL; Zhao Z; Yang H; Liu FF; Liu Q; Luo Q; Yuan Q; Chen LM; Zeng AZ
    J Viral Hepat; 2013 Sep; 20(9):645-9. PubMed ID: 23910649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients.
    Urata Y; Uesato R; Tanaka D; Kowatari K; Nitobe T; Nakamura Y; Motomura S
    Mod Rheumatol; 2011 Feb; 21(1):16-23. PubMed ID: 20668905
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence.
    Inuzuka T; Ueda Y; Morimura H; Fujii Y; Umeda M; Kou T; Osaki Y; Uemoto S; Chiba T; Marusawa H
    J Hepatol; 2014 Sep; 61(3):492-501. PubMed ID: 24798622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.